Year |
Citation |
Score |
2022 |
Cheung R, Ito E, Lopez M, Rubinstein E, Keller H, Cheung F, Liu ZA, Liu FF, Wong P. Evaluating the Short-Term Environmental and Clinical Effects of a Radiation Oncology Department's Response to the COVID-19 Pandemic (STEER COVID-19). International Journal of Radiation Oncology, Biology, Physics. PMID 36309074 DOI: 10.1016/j.ijrobp.2022.04.054 |
0.374 |
|
2021 |
Harnett N, Tosoni S, Brandt C, Ito E, Milne E, Liu FF, Wong R. Accelerated Education Program in Radiation Medicine: International Learner Perceptions of Experiences, Outcomes, and Impact. International Journal of Radiation Oncology, Biology, Physics. 109: 656-660. PMID 33516435 DOI: 10.1016/j.ijrobp.2020.09.051 |
0.368 |
|
2020 |
Ito E, Moraes FY, Ramotar M, Lunsky I, Soliman H, Catton CN, Kassam Z, Morton G, Tosoni S, Gospodarowicz M, Wong RKS, Liu FF, Chung PWM. Radiation Oncology Fellowship: a Value-Based Assessment Among Graduates of a Mature Program. Journal of Cancer Education : the Official Journal of the American Association For Cancer Education. PMID 32683629 DOI: 10.1007/S13187-020-01767-5 |
0.371 |
|
2015 |
Bruce JP, Yip K, Bratman SV, Ito E, Liu FF. Nasopharyngeal Cancer: Molecular Landscape. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26351340 DOI: 10.1200/Jco.2015.60.7846 |
0.612 |
|
2014 |
Williams JP, Kim I, Ito E, Shi W, Yue S, Siu LL, Waldron J, O'Sullivan B, Yip KW, Liu FF. Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma. Plos One. 9: e98557. PMID 24853121 DOI: 10.1371/Journal.Pone.0098557 |
0.547 |
|
2013 |
Lenarduzzi M, Hui AB, Yue S, Ito E, Shi W, Williams J, Bruce J, Sakemura-Nakatsugawa N, Xu W, Schimmer A, Liu FF. Hemochromatosis enhances tumor progression via upregulation of intracellular iron in head and neck cancer. Plos One. 8: e74075. PMID 23991213 DOI: 10.1371/Journal.Pone.0074075 |
0.688 |
|
2013 |
Ito E, Yue S, Moriyama EH, Hui AB, Kim I, Shi W, Alajez NM, Bhogal N, Li G, Datti A, Schimmer AD, Wilson BC, Liu PP, Durocher D, Neel BG, et al. Targeting uroporphyrinogen decarboxylase for head and neck cancer treatment Bmc Proceedings. 7. DOI: 10.1186/1753-6561-7-S2-P19 |
0.557 |
|
2012 |
P'ng C, Ito E, How C, Bezjak A, Bristow R, Catton P, Fyles A, Gospodarowicz M, Jaffray D, Kelley S, Wong S, Liu FF. Excellence in Radiation Research for the 21st Century (EIRR21): description of an innovative research training program. International Journal of Radiation Oncology, Biology, Physics. 83: e563-70. PMID 22520480 DOI: 10.1016/J.Ijrobp.2012.02.035 |
0.593 |
|
2012 |
Williams JP, Kim I, Yue S, Shi W, Ito E, Siu LL, Waldron J, Liu F. Abstract 2879: Pre-clinical characterization of Dacomitinib, an irreversible pan-HER inhibitor, combined with radiation therapy in head and neck cancer models Cancer Research. 72: 2879-2879. DOI: 10.1158/1538-7445.Am2012-2879 |
0.531 |
|
2011 |
Hui A, How C, Ito E, Liu FF. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. Bmc Cancer. 11: 500. PMID 22128797 DOI: 10.1186/1471-2407-11-500 |
0.709 |
|
2011 |
Ito E, Yip KW, Liu FF. Uroporphyrinogen decarboxylase: optimizing radiotherapy for head and neck cancer. Future Oncology (London, England). 7: 595-7. PMID 21568673 DOI: 10.2217/Fon.11.27 |
0.493 |
|
2011 |
Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, O'Sullivan B, Liu FF. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Research. 71: 2381-91. PMID 21385904 DOI: 10.1158/0008-5472.Can-10-2754 |
0.705 |
|
2011 |
Ito E, Yue S, Moriyama EH, Hui AB, Kim I, Shi W, Alajez NM, Bhogal N, Li G, Datti A, Schimmer AD, Wilson BC, Liu PP, Durocher D, Neel BG, et al. Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Science Translational Medicine. 3: 67ra7. PMID 21270338 DOI: 10.1126/Scitranslmed.3001922 |
0.584 |
|
2010 |
Alajez NM, Shi W, Hui AB, Bruce J, Lenarduzzi M, Ito E, Yue S, O'Sullivan B, Liu FF. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death & Disease. 1: e85. PMID 21368858 DOI: 10.1038/Cddis.2010.64 |
0.701 |
|
2010 |
Razak AR, Siu LL, Liu FF, Ito E, O'Sullivan B, Chan K. Nasopharyngeal carcinoma: the next challenges. European Journal of Cancer (Oxford, England : 1990). 46: 1967-78. PMID 20451372 DOI: 10.1016/J.Ejca.2010.04.004 |
0.515 |
|
2010 |
Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, Gilbert R, Liu FF. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. International Journal of Radiation Oncology, Biology, Physics. 77: 253-60. PMID 20394857 DOI: 10.1016/J.Ijrobp.2009.11.027 |
0.525 |
|
2010 |
Kato H, Ito E, Shi W, Alajez NM, Yue S, Lee C, Chan N, Bhogal N, Coackley CL, Vines D, Green D, Waldron J, Gullane P, Bristow R, Liu FF. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 898-911. PMID 20103674 DOI: 10.1158/1078-0432.Ccr-09-1945 |
0.535 |
|
2010 |
Shi W, Alajez NM, Bastianutto C, Hui AB, Mocanu JD, Ito E, Busson P, Lo KW, Ng R, Waldron J, O'Sullivan B, Liu FF. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. International Journal of Cancer. Journal International Du Cancer. 126: 2036-48. PMID 19739117 DOI: 10.1002/Ijc.24880 |
0.619 |
|
2010 |
Ito E, Yue S, Moriyama EH, Hui AB, Kim I, Shi W, Alajez NM, Bhogal N, Li G, Datti A, Schimmer AD, Wilson BC, Liu PP, Durocher D, Neel BG, et al. Abstract SSY01-03: An RNAi screen identifies a heme biosynthetic mediator as a novel radiosensitizing target for head and neck cancer Tumor Biology. DOI: 10.1158/1538-7445.Am10-Ssy01-03 |
0.506 |
|
2009 |
Ito E, Yip KW, Katz D, Fonseca SB, Hedley DW, Chow S, Xu GW, Wood TE, Bastianutto C, Schimmer AD, Kelley SO, Liu FF. Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. Molecular Pharmacology. 76: 969-83. PMID 19654225 DOI: 10.1124/Mol.109.055277 |
0.524 |
|
2009 |
Hui AB, Yue S, Shi W, Alajez NM, Ito E, Green SR, Frame S, O'Sullivan B, Liu FF. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3716-24. PMID 19470731 DOI: 10.1158/1078-0432.Ccr-08-2790 |
0.506 |
|
2009 |
Katz D, Ito E, Liu FF. On the path to seeking novel radiosensitizers. International Journal of Radiation Oncology, Biology, Physics. 73: 988-96. PMID 19251086 DOI: 10.1016/J.Ijrobp.2008.12.002 |
0.487 |
|
2008 |
Katz D, Ito E, Lau KS, Mocanu JD, Bastianutto C, Schimmer AD, Liu FF. Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. Biotechniques. 44: ix-xiv. PMID 18422490 DOI: 10.2144/000112757 |
0.485 |
|
2006 |
Yip KW, Ito E, Mao X, Au PY, Hedley DW, Mocanu JD, Bastianutto C, Schimmer A, Liu FF. Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Molecular Cancer Therapeutics. 5: 2234-40. PMID 16985057 DOI: 10.1158/1535-7163.Mct-06-0134 |
0.501 |
|
Show low-probability matches. |